SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-305187
Filing Date
2023-12-28
Accepted
2023-12-28 16:30:30
Documents
12
Period of Report
2023-12-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d473634d8k.htm   iXBRL 8-K 24141
  Complete submission text file 0001193125-23-305187.txt   145592

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20231222.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20231222_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20231222_pre.xml EX-101.PRE 11257
6 EXTRACTED XBRL INSTANCE DOCUMENT d473634d8k_htm.xml XML 3352
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 231523034
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)